Compounded GLP-1 RA drugs: A continuing discussion about GLP-1 RA drugs, the perfect storm of demand and shortages, part 2

Scott Brunner, CAE, CEO of the Alliance for Pharmacy Compounding, continues his description about GLP-1 RA drugs in the landscape of contemporary American health care. Did anyone anticipate the duration of the shortage of the drugs, or the demand for them, or the prices? The antidiabetes and antiobesity drugs are a phenomenon in the American health care system. Spoiler alert: While there has been much public scrutiny about prices of GLP-1 RAs, compounded drugs are not necessarily cheaper than those made by pharmaceutical companies.